Published in Cancer Treat Res on January 01, 1991
The association of breast mitogens with mammographic densities. Br J Cancer (2002) 2.25
Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res (2003) 1.53
Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis (2011) 1.10
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res (2012) 1.01
Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer (1992) 1.00
Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Mol Cancer Res (2011) 0.94
Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix. Br J Cancer (2002) 0.89
Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer (2002) 0.87
Seed in soil, with an epigenetic view. Biochim Biophys Acta (2008) 0.86
Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 6.58
A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell (2000) 6.14
Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 5.73
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem (1998) 3.25
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res (2001) 3.02
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A (1996) 2.90
DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol (1979) 2.63
Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun (1996) 2.50
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol (2011) 2.47
Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain. Mamm Genome (1997) 2.47
Genotype-based screen for ENU-induced mutations in mouse embryonic stem cells. Nat Genet (2000) 2.24
The IGF system and breast cancer. Endocr Relat Cancer (2001) 2.21
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 2.08
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res (1995) 2.04
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Chronic respiratory disease in a rural community. Lancet (1968) 2.00
Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem (1995) 1.98
When is Helicobacter pylori infection acquired? Gut (1993) 1.94
Electroporation: parameters affecting transfer of DNA into mammalian cells. Anal Biochem (1987) 1.94
Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci U S A (1987) 1.92
Genetic deletion of a neural cell adhesion molecule variant (N-CAM-180) produces distinct defects in the central nervous system. Neuron (1993) 1.74
Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem (1986) 1.67
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Atrial fibrillation and mortality in an elderly population. Aust N Z J Med (1989) 1.61
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest (1995) 1.61
FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology (1999) 1.61
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res (1997) 1.54
Isolation of variants in phagocytosis of a macrophage-like continuous cell line. J Exp Med (1977) 1.54
Sensitivity and selectivity in protein similarity searches: a comparison of Smith-Waterman in hardware to BLAST and FASTA. Genomics (1996) 1.53
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res (1988) 1.53
Increased pp60c-src tyrosyl kinase activity in human neuroblastomas is associated with amino-terminal tyrosine phosphorylation of the src gene product. Proc Natl Acad Sci U S A (1985) 1.52
Molecular Differentiation and Detection of Ginseng-Adapted Isolates of the Root Rot Fungus Cylindrocarpon destructans. Phytopathology (2003) 1.52
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res (1999) 1.51
A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene (1994) 1.51
Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene (2001) 1.51
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res (2001) 1.50
A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol (2001) 1.49
The prevalence and nature of podiatric problems in elderly diabetic patients. J Am Geriatr Soc (1991) 1.49
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer (2006) 1.49
Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res (1987) 1.49
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene (2009) 1.48
Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest (1990) 1.44
A six-year controlled trial of prevention of children's behavior disorders. J Pediatr (1976) 1.41
Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc Natl Acad Sci U S A (1999) 1.40
New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches. Pharmacol Res (1999) 1.39
Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition. Mol Cell Biol (2000) 1.38
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res (1991) 1.36
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A (1998) 1.35
Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects. Breast Cancer Res Treat (1999) 1.33
The albino-deletion complex in the mouse defines genes necessary for development of embryonic and extraembryonic ectoderm. Development (1989) 1.32
Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res (1988) 1.32
Mass health examinations in the Busselton population, 1966 to 1970. Med J Aust (1972) 1.30
Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells. Oncogene Res (1987) 1.29
Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem (1998) 1.29
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res (2000) 1.26
Self-concepts, domain values, and self-esteem: relations and changes at early adolescence. J Pers (1989) 1.26
The prevalence of coronary heart disease and associated factors in an Australian rural community. Am J Epidemiol (1969) 1.25
Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene (2010) 1.23
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res (2000) 1.21
The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene (2009) 1.20
Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol (1997) 1.19
Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res (2000) 1.16
Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem (1989) 1.15
Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res (2000) 1.13
The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr Cancer Drug Targets (2008) 1.13
Carcinoembryonic antigen in an unselected elderly population: a four year follow up. Br J Cancer (1975) 1.13
Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res (1995) 1.12
Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst (1996) 1.10
The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ (2000) 1.10
Cloning, chromosome localization, expression, and characterization of an Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10gamma. J Biol Chem (1997) 1.09
Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst (1992) 1.09
Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett (1999) 1.08
Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics (2001) 1.08
Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene (2000) 1.07
Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes. Br J Ophthalmol (1983) 1.06
Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res (1996) 1.05
Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J (1999) 1.05
Cholesterol and the child: studies of the cholesterol levels of Busselton school children and their parents. Aust Paediatr J (1972) 1.05
The albino deletion complex and early postimplantation survival in the mouse. Development (1988) 1.04
Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res (1998) 1.03
Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol (2000) 1.03
Insulin-like growth factors and breast cancer. Biomed Pharmacother (1995) 1.01
Modulation of Fc-mediated phagocytosis by cyclic AMP and insulin in a macrophage-like cell line. J Immunol (1977) 1.00
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells. Oncogene Res (1987) 1.00
Expression of insulin-like growth factor-II mRNA in fetal kidney and Wilms' tumor. An in situ hybridization study. Lab Invest (1989) 0.99
Complications from planned, posttreatment neck dissections. Arch Otolaryngol Head Neck Surg (1999) 0.99
Genetic approaches to the mechanism of macrophage functions. Fed Proc (1978) 0.99
Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg Med Chem Lett (2000) 0.97
Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem (1993) 0.97